Class Action Lawsuit Filed Against Pacira BioSciences, Inc.: What Does This Mean for Investors and the World?
NEW YORK, March 09, 2025 – In a significant development for the biopharmaceutical industry, Bronstein, Gewirtz & Grossman, LLC, a leading national law firm, has announced the filing of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers. The lawsuit alleges that Pacira and its executives made false and misleading statements and failed to disclose material information to investors.
Background on Pacira BioSciences, Inc.
Pacira BioSciences is a New Jersey-based biotech company that develops and commercializes innovative pain management and regenerative health solutions for acute care, orthopedic, and sports medicine markets. The Company’s flagship product is EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid local anesthetic indicated for single-dose surgical procedures to produce postsurgical resident analgesia.
Details of the Class Action Lawsuit
The complaint, filed in the United States District Court for the District of New Jersey, alleges that Pacira and its executives made false and misleading statements and failed to disclose material information regarding the safety and efficacy of EXPAREL, as well as the Company’s financial performance and business prospects. Specifically, the lawsuit alleges that the defendants misrepresented the following:
- The safety and efficacy of EXPAREL, including its risk of serious adverse events such as cardiac arrest and hypotension;
- The financial performance of Pacira, including its revenue growth and earnings;
- The Company’s business prospects, including its ability to maintain its market position and compete with competitors.
As a result of these alleged misrepresentations, Pacira’s stock traded at artificially inflated prices between February 22, 2021, and March 9, 2023. When the truth was revealed, the price of Pacira’s stock dropped significantly, causing harm to investors.
Impact on Individual Investors
For individual investors, the class action lawsuit against Pacira BioSciences could result in significant financial losses. If the defendants are found liable for securities fraud, investors may be eligible to recover their losses through the class action settlement. The exact amount of damages that may be recovered will depend on the outcome of the lawsuit and the size of the class.
Global Implications
The class action lawsuit against Pacira BioSciences has broader implications for the biopharmaceutical industry and the investment community as a whole. It underscores the importance of accurate and transparent disclosures, particularly in the context of emerging technologies and complex scientific research. The lawsuit also highlights the risks associated with investing in biotech companies, which can be subject to significant regulatory scrutiny and market volatility.
Conclusion
The class action lawsuit against Pacira BioSciences, Inc. marks a significant development in the biopharmaceutical industry and the investment community. It serves as a reminder of the importance of accurate and transparent disclosures, particularly in the context of emerging technologies and complex scientific research. For individual investors, the lawsuit highlights the risks associated with investing in biotech companies and the potential for significant financial losses. As the case unfolds, it will be important for investors to stay informed and seek professional advice to minimize their risk and maximize their potential returns.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities fraud class actions and other complex litigation. The firm has recovered billions of dollars for investors harmed due to securities fraud, corporate fraud, and other class action claims. If you are a Pacira BioSciences investor and have lost money on your investment, you are encouraged to contact the firm for a free consultation.
The foregoing information is intended to provide general information only and is not intended as legal advice. You should consult an attorney for advice regarding your specific situation.
